2022 in review

Looking back: Top 5 most-read Houston space tech articles of the year

Here's what Houston tech and startup news trended this year in InnovationMap's space tech category. Photo via NASA

Editor's note: As 2022 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the Space City, there were dozens of space tech stories, from experts' thoughts on commercialization to the IPO of a Houston company. Here are five Houston space tech-focused articles that stood out to readers this year — be sure to click through to read the full story.

Overheard: Houston needs to strengthen infrastructure, workforce to maintain Space City status

Space experts discussed the city's role in the space industry at a recent event. Photo via NASA

In no time at all, humans will return to the moon and as they make the first spacewalks in fifty years — wearing suits designed in Houston — they will call down to earth, and only one city in the world will be named on the radio transmissions.

Houston is the Space City — but what will it take to maintain that moniker? This was a big topic of the Greater Houston Partnership's second annual State of Space event hosted on Tuesday, October 11.

A diverse and impressive panel discussed the Space City's future, the upcoming moon missions, commercializations, and more. Read more.

Houston-based space tech company to go public via SPAC merger

The deal between Intuitive Machines and a SPAC is expected to close in the first quarter of 2023 and would value the combined company at $815 million. Photo courtesy of Intuitive Machines

A Houston-based space exploration company that’s been tapped by NASA to take cargo to the moon plans to go public through a SPAC merger with a New York-based shell company.

Intuitive Machines LLC, founded in 2013, aims to merge with New York City-based Inflection Point Acquisition Corp., a special purpose acquisition company (SPAC). Once the merger is completed, shares of the combined company (Intuitive Machines) will trade on the Nasdaq stock market under the ticker symbol LUNR.

The deal, expected to close in the first quarter of 2023, would value the combined company at $815 million. Read more.

Space City News: Houston Spaceport receives grant, unicorn hires architecture firm

Catch up on two big pieces of news landing at the Houston Spaceport. Image via fly2houston.com

The Space City is starting 2022 off strong with news launching out of the Houston Spaceport — a 400-acre space in Southeast Houston.

The two big headlines include a unicorn company releasing the latest details of its earthbound project and fresh funds from the state to support the space ecosystem in Texas. Read more.Read more.

Overheard: Space experts discuss commercialization, innovation, and Houston's future

What's Houston's role in the modern era for aerospace? And how can the industry foster public-private collaboration? Experts weighed in at a recent event. Photo via NASA

The aerospace industry — much more than other sectors — is run by a mixture of civil, commercial, and military players. And each of these verticals operate very differently.

At a Houston Tech Rodeo event called "Lasso the Moon" put on by Space Force Association and TexSpace, aerospace experts representing various entities — from startups to big tech to education and military organizations — discussed the future of space innovation. Read more.

Iconic Houston-area landmark rockets to No. 1 in new list of best employers in Texas

Johnson Space Center astronauts and team enjoy the best workplace in Texas. Johnson Space Center/Facebook

NASA must be over the moon about a new ranking of the best employers in Texas.

A new list from Forbes and Statista puts NASA at No. 1 among the state’s major employers, both those based in Texas and those with a significant presence here.

NASA’s $1.5 billion Johnson Space Center complex occupies more than 1,600 acres in Clear Lake. The site, home to the space agency’s mission control and astronaut training operations, employs roughly 3,000 NASA workers, along with thousands of NASA contractors. NASA’s headquarters is in Washington, D.C.

It’s estimated that Johnson Space Center contributed more than $4.7 billion to the Texas economy in 2018. Read more.

Trending News

Building Houston

 
 

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo via Getty Images

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release.

The company is developing proprietary therapies to enhance the function of regulatory T cells to target systemic inflammation and neuroinflammation.

According to the company, the net proceeds from the offering — which was estimated to be at around $13.2 million, per a release — will go toward advancing its programs in preclinical studies into clinical trials — as well as to advance its discovery and candidate selection stage programs and other scaling purposes.

A year ago, Coya Therapeutics announced that it had merged with Nicoya Health Inc. and raised $10 million in its series A. The round was led by Florida-based Allele Capital Partners LLC. Howard Berman, founder and board of directors for imaware, was named the CEO of Coya, as well as a member of the company's board of directors, alongside the merger and series A announcement.

Coya's therapeutics uses innovative work from Dr. Stanley H. Appel, co-director of Houston Methodist Neurological Institute and Chair of the Stanley H. Appel Department of Neurology at Houston Methodist Hospital. The researcher has created a way to "isolate dysfunctional Tregs from a patient, convert them to a highly functional and neuroprotective condition, and expand these cells into the billions for intravenous reinfusion back to the patient," says Berman in a 2022 news release. This revolutionary work overcomes previous limitations in the field.

"Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuroprotective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm and may enable us to revolutionize care for patients with devastating neurodegenerative diseases," Appel said last February. "We have successfully demonstrated, in a phase 1 trial, the safety and tolerability of autologous infusions of expanded Tregs in ALS patients, with the potential of slowing or halting disease progression. Ongoing studies provide a transformative framework for advanced clinical trials in ALS and other neurodegenerative disorders."

Trending News